| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Luminex Corporation |
| 12212 Technology Boulevard, Austin, TX 78727 * (512) 219-8020 |
| Business Description | The company has developed, manufactures and markets a proprietary technology platform that simplifies biological testing for the life sciences industry. |
| Offering Information Company has | |||
| Trading As | LMNX (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/7/00 |
| Domestic Shares Offered | 4,500,000 | Offer Date | 3/29/00 |
| Foreign Shares Offered | 0 | Filing Range | $17.00 - $19.00 |
| Company Shares | 4,500,000 | Offer Price | $17.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.190 |
| Gross Proceeds | $76,500,000 | Selling | $0.670 |
| Expenses | $700,000 | Reallowance | $0.100 |
| Post-IPO Shares | 26,472,821 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Warburg Dillon Read LLC | Lead Manager | (203) 719-3000 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | 0.000 | 0.000 | 0.099 | 0.386 | 3.112 | - | - |
| Income from Oper. | -0.274 | -1.767 | -2.931 | -5.879 | -8.732 | - | - |
| Net Income | -0.270 | -1.760 | -2.753 | -5.596 | -8.448 | - | - |
| E.P.S | -0.120 | -0.330 | -0.440 | -0.870 | -1.310 | - | - |
| Revenue Growth (%) | - | - | 289.90 | 706.218 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -8.38 | - | - | ||||
| Cash Flow - Inv. | -6.01 | - | - | ||||
| Cash Flow - Fin. | 9.94 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 12.57 | Current Assets | 11.20 | Current Ratio | 14.52 |
| Total Liab. | 1.37 | Current Liab. | 0.77 | Debt Ratio | 10.91% |
| Total Equity | 11.20 | Working Cap. | 10.43 | Debt to Equity Ratio | 0.12 |
| Cash | 4.08 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund our operations, including continued development and manufacturing of existing products and research and development of additional products, expanding our facilities to be able to meet the needs of our growing business, and for working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Thompson & Knight |
| Bank's Law Firm | Dewey Ballantine |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |